Organogenesis Holdings Inc.NASDAQ: ORGO

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

Apr 6, 2026 · Issued by Organogenesis Holdings Inc.

Watch Organogenesis explain itOrganogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call · Replay · Aug 6

Statistically significant (p

Company analysis

Earlier from Organogenesis

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record RevenueFeb 26
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026Feb 19
Organogenesis Announces Initiation of Biologics License Application for ReNu®Dec 23, 2025

All Organogenesis news releases